

REMARKS

The Amendments to the Specification

The specification was amended by replacing the existing Cross Reference to Related Applications section with an updated Cross Reference to Related Applications section.

The Amendments to the Claims


Claim 1 was amended by deletion of the term 'O' from the definition of variable X and by deletion of the term 'thienyl' and the proviso from the definition of variable Z. Claim 2 was amended by deletion of the thienyl moiety from the definition of variable Z. Claim 4 was amended by replacement of the thienyl moiety with a phenyl moiety in the definition of variable Z. Applicants submit that the amendments to claims 1, 2 and 4 were made in order to remove subject matter from the present claims that is covered by U.S. Patent 6,552,067 and allowed application U.S.S. N. 10/326,366. Claim 9 was amended by deletion of the previous group of compounds and by addition of a new list of compounds. The previous list of compounds was deleted because a claim to these compounds was allowed in U.S.S. N. 10/326,366. Support for the new list of compounds in claim 9 is in the specification from page 54 to page 106. Particularly, the title compounds of Examples 1A-1H, 2A-2K, 4A-4B and 5A-5B have been added by this amendment. Method of treatment claims 22 and 23 have been added. Claim 22 covers the treatment of conditions that present with impaired renal function in a mammal, such as renal osteodystrophy and diabetic nephropathy. Support for claim 22 is in the specification at page 11, lines 26-30 and page 41, line 21 through page 42, line 7. Support for claim 23 is in the specification at page 11, lines 20-25. Applicants submit that no new matter has been added by these amendments.

Should any fees be required in connection with this Preliminary Amendment, authorization is hereby given to charge any fees or refund any fees overpaid to deposit account number 16-1445. Applicants believe the application, as amended, is in condition for allowance. An early and favorable response is respectfully requested.

Respectfully submitted,

Date: 23 SEPTEMBER 2003

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6645

A handwritten signature in black ink, appearing to read "John A. Wichtowski", is written over a horizontal line.

John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032